Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules (US RLD: Reyataz™ Capsules) in the strengths of 150 mg, 200 mg and 300 mg.
Atanazavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV). It is used in combination with other antiretroviral drugs to treat HIV-1 infection.
The drug will be manufactured at the group's manufacturing facility at SEZ, Anmedabad.
The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.362.9 as compared to the previous close of Rs. 354. The total number of shares traded during the day was 267884 in over 4516 trades.
The stock hit an intraday high of Rs. 363.9 and intraday low of 353.75. The net turnover during the day was Rs. 96147344.